At the AACR 2025 Annual Meeting, Yuhan Corporation unveiled promising preclinical results for two of its cancer drug candidates: YH42946, a HER2/EGFR tyrosine kinase inhibitor (TKI), and YH32364, an EGFR×4-1BB bispecific antibody co-developed with ABL Bio.
YH42946, licensed from J INTS BIO in 2023, targets tumors with HER2 and EGFR exon 20 insertions, mutations often resistant to conventional TKIs, especially in non-small cell lung cancer (NSCLC). Preclinical studies using patient-derived cells demonstrated potent inhibition across a broad range of HER2 and EGFR mutations, including HER2 amplification and overexpression. A global Phase 1/2 clinical trial is already underway in patients with advanced solid tumors harboring these genetic alterations.
YH32364, also known as ABL104, is a bispecific antibody that selectively binds EGFR-expressing tumor cells to block growth signals while stimulating 4-1BB-mediated T cell activation. In vitro studies showed strong antitumor activity in EGFR+/KRAS-mutant lung and colorectal cancer cell lines, outperforming competitor compounds. In vivo models confirmed immune cell infiltration, enhanced tumor microenvironment, and durable antitumor effects, particularly in head and neck cancers, where synergy with anti-PD-1 antibodies was observed.
YH32364 recently received IND clearance from South Korea’s Ministry of Food and Drug Safety and is expected to enter clinical trials in the first half of 2025.
To learn more, please click here: https://www.thebionews.net/news/articleView.html?idxno=14755
#Yuhan, #YuhanUSA, #YH42946, #YH32364